Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study

• 主要な著者: Gordon D (著者), Hellriegel ET (著者), Hope HR (著者), Burt D (著者), Monahan JB (著者)
• フォーマット: 図書
• 出版事項: Dove Medical Press, 2021-06-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

David Gordon,1 Edward T Hellriegel,1 Heidi Rath Hope,2 David Burt,1 Joseph B Monahan2 1Research and Development, Aclaris Therapeutics, Inc., Wayne, PA, USA; 2Research and Development, Aclaris Therapeutics, Inc., and Confluence Discovery Technologies, Inc., St. Louis, MO, USACorrespondence: David Gor...